Gilead Sciences Newswire

Comprehensive Real-Time News Feed for Gilead Sciences.

Results 1 - 20 of 892 in Gilead Sciences

  1. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Saturday Apr 25 | Business Wire

    ... dat op Sofosbuvir gebaseerde regimes bij chronische hepatitis C-patinten met genotypen 2-5 evalueert )--Gilead Sciences, Inc. (Nasdaq: GILD) heeft vandaag de resultaten bekendgemaakt van twee onderzoeken waarin de veiligheid en werkzaamheid worden ...


  2. Morningstar Issues "A+" Credit Rating to Gilead SciencesRead the original story

    9 hrs ago |

    Gilead Sciences has received an "A+" credit rating from Morningstar . The research firm's "A+" rating suggests that the company is a low default risk.


  3. FireEye, Gilead Sciences, and Aeropostale: Doug Kass' ViewsRead the original story

    16 hrs ago |

    Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 9+ You may proceed to the site by clicking here , however some pages might not work correctly.


  4. Specialty Drug Costs: Hard Pills to SwallowRead the original story w/Photo

    Yesterday | Workforce

    ... new and better medicines were on the horizon, she decided to wait. Three months later, pharmaceutical firm Gilead Sciences Inc. released Sovaldi, a drug with fewer side effects that could cure hepatitis C. In April 2014 she began a three-month ...


  5. Deutsche Bank Reaffirms Buy Rating for Gilead SciencesRead the original story

    Yesterday |

    ... stock. Deutsche Bank's price target points to a potential upside of 11.90% from the stock's previous close. Gilead Sciences ( NASDAQ:GILD ) traded up 0.44% on Friday, hitting $111.71. The stock had a trading volume of 12,079,030 shares. Gilead ...


  6. Gilead Sciences Given Overweight Rating at Morgan StanleyRead the original story

    Saturday |

    Other equities research analysts have also recently issued reports about the stock. Analysts at RBC Capital set a $120.00 price target on shares of Gilead Sciences and gave the company a "buy" rating in a research note on Wednesday, May 13th.


  7. As Market Roars, Gilead Looking for "Value-Added" Deals, Says CFORead the original story

    Thursday May 21 | BioSpace

    May 22, 2015 By Riley McDermid , Breaking News Sr. Editor Booming biotech Gilead Sciences, Inc. is looking for "value-added" deals as opposed to ones that create synergies, the company's chief financial officer told attendees at the UBS 2015 Global Healthcare Conference in New York this week, renewing speculation that Gilead may be looking to buy a large pharmaceutical operation with an existing research and development and manufacturing arm. CFO Robin Washington said Gilead is currently using an "operationally leveraged model" that looks at M&A that don't interfere with Gilead's "big picture" plans.


  8. 10 S&P 500 Companies to Have the Most Revenue Growth in 2015Read the original story w/Photo

    Wednesday May 20 |

    ... IQ Rating/Price Target: Strong Buy/$143 PT TheStreet Ratings: Buy, A TheStreet Ratings said: "We rate GILEAD SCIENCES INC (GILD) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the ...


  9. Compulsory licensing sought for hepatitis C medicationRead the original story w/Photo

    Wednesday May 20 | The Nation

    ... his objective was to ask the Public Health Ministry to implement compulsory licensing for sofosbuvir in case Gilead Sciences Inc successfully registers a patent for this drug in Thailand. "This drug is very important to hepatitis C patients, so the ...


  10. Diane McKeel did not disclose connection between her son, her proposed $200,000 HIV campaignRead the original story w/Photo

    Thursday May 21 |

    ... to disclose that her son works for the drug's maker. Ryan McKeel, formerly an AIDS activist, now works for Gilead Sciences, a drug maker that has been controversial in recent years for its pricing practices. Last week, McKeel introduced a budget ...


  11. Gilead Sciences: Finally Gaining MomentumRead the original story w/Photo

    Wednesday May 20 | Seeking Alpha

    ... over the past nine months, moved up some five percent over five trading sessions. That stock, of course, is Gilead Sciences (NASDAQ: GILD ) , which is the largest position in my portfolio, and one that I talk about often here on Seeking Alpha. This ...


  12. Curing hepatitis C could yield huge economic benefitRead the original story

    Monday May 18 | Medical News Today

    ... May 17 at the Walter E. Washington Convention Center. This study was funded through a grant provided by Gilead Sciences, Inc. MLA Week, Digestive Disease. "Curing hepatitis C could yield huge economic benefit ." Medical News Today . MediLexicon, ...


  13. Big spending on big ideas does bring a big payoffRead the original story w/Photo

    Wednesday May 20 | The Peninsula

    ... giants like Yahoo! Inc. and Adobe Systems Inc., science pacesetters like Vertex Pharmaceuticals Inc. and Gilead Sciences Inc., and makers of engineered products like cars, airplanes and electronics gear. Financial companies and sellers of consumer ...


  14. Achillion, Johnson & Johnson Hammer Out $1 Billion+ Hep C R&D Pact to ...Read the original story

    Tuesday May 19 | BioSpace

    ... in December and it quickly gained the attention of anyone trying to treat or cure the disease. Market leader Gilead Sciences, Inc. (GILD) has been feeling pressured by ACH-3102, which has shown promising Phase II results when combined with Gilead's ...


  15. Quant Picks: 3 Biotech Companies to Add to Your PortfolioRead the original story w/Photo

    Tuesday May 19 |

    ... 'A-' rating, the company's strengths can be seen in its revenue growth and notable return on equity.2nd is, Gilead Sciences. This rating is an 'A.' Gilead thrives in its growth in earnings per share and compelling growth in net income. Number 1 is ...


  16. Twitter Attempts to Marry Gilead, Achillion, Finds Reality InsteadRead the original story

    Monday May 18 | BioSpace

    May 19, 2015 By Riley McDermid , Breaking News Sr. Editor Biotech darling Gilead Sciences, Inc. was almost the brand new owner of rival drugmaker Achillion Pharmaceuticals, Inc. yesterday-if only on Twitter . Rumors ran rampant on the social media site yesterday that Gilead had canceled an appearance at the same health conference Achillion had bowed out of because the two were in talks for a deal.


  17. Woman sues Anthem Blue Cross for refusing to cover hepatitis C drugRead the original story w/Photo

    Monday May 18 | Los Angeles Times

    ... to her child. It's unconscionable, Andre said, that Anthem won't pay for the drug, which is manufactured by Gilead Sciences Inc. of Foster City, near San Francisco. "I can't believe that they demand that a person get sicker before they'll pay for a ...


  18. Gilead Sciences to Present at the UBS 2015 Global Healthcare Conference on Tuesday, May 19Read the original story

    Monday May 18 | Freshnews

    Gilead Sciences, Inc. today announced that its corporate presentation will be webcast from the UBS 2015 Global Healthcare Conference in New York. Robin Washington, Gilead's Executive Vice President and Chief Financial Officer, will provide an overview of the company at the conference on Tuesday, May 19 at 10:00 a.m. Eastern Time.


  19. Gilead Sciences Sees Large Decrease in Short InterestRead the original story

    Monday May 18 |

    Gilead Sciences saw a significant drop in short interest in the month of April. As of April 30th, there was short interest totalling 55,507,917 shares, a drop of 3.3% from the April 15th total of 57,428,704 shares, ARN reports.


  20. Liver Conference Previews the Future of Hep C TreatmentRead the original story w/Photo

    Monday May 18 | POZ

    ... with hep C, the 2015 gathering focused more on fine-tuning the armamentarium against the virus. After all, Gilead Sciences' Harvoni (ledipasvir/sofosbuvir), approved by the U.S. Food and Drug Administration (FDA) in October 2014, already boasts ...